Participation of the Monoaminergic System in the Antidepressant-Like Actions of Estrogens: A Review in Preclinical Studies by Carolina López-Rubalcava et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
3 
Participation of the Monoaminergic System in 
the Antidepressant-Like Actions of Estrogens: 
A Review in Preclinical Studies 
Carolina López-Rubalcava1, Nelly Maritza Vega-Rivera1,2,  
Nayeli Páez-Martínez3 and Erika Estrada-Camarena2* 
1Departamento de Farmacobiología, Cinvestav-IPN,  
2Laboratorio de Neuropsicofarmacología,  
Instituto Nacional de Psiquiatria Ramón de la Fuente,  
3Sección de Graduados, Escuela Superior de Medicina-IPN 
Mexico 
1. Introduction 
1.1 Estrogen receptors – Classification and distribution 
Estrogens are steroid hormones produced by gonads that bind to different receptor types 
and mediate numerous actions, like growth, development, cognition, neuroprotection and 
participate in mood regulation (Margeat et al., 2003; Vasudevan & Pfaff, 2007). The classic 
estrogen receptors (ER) are: ER┙ and ER┚. These receptors are  ligand-activated 
transcription factors (Kuiper & Gustafsson, 1997) with nuclear and non-nuclear distribution 
(Monje & Boland, 2001; Weiser et al., 2008).  In ovariectomized rats, ER┚ and ER┙ are co-
localized in various brain regions, including the bed nucleus of the stria terminalis, the 
medial and cortical amygdaloid nuclei, the preoptic area, the lateral habenula, the 
periacueductal gray, the locus coeruleus, the hippocampus and the brain cortex (Shughrue 
et al., 1997). In these last two structures, ER┚ is more abundant than ER┙. Other structures 
that contain only ER┚ are the olfactory bulb, the ventral tegmental area, the zona incerta, the 
cerebellum, the pineal gland and some hypothalamic nuclei (such as the supraoptic, the 
paraventricular, the supraquiasmatic and the tuberal nuclei). By contrast, brain areas with 
solely ER┙ are the ventromedial hypothalamic nuclei and the subfornical organ (Shughrue 
et al., 1997).  
Several reports have described two membrane estrogen receptors unrelated to ER┙ and 
ER┚: an orphan receptor coupled to G proteins called GPR30 (Filardo et al., 2002) and 
another, named ER-X, that posses characteristics of tyrosine-kynase activity (Toran-
Allerand, 2004). GPR30 is a seven transmembrane ER that binds estrogens with high affinity 
and acts independently of ER┙ and ER┚ to stimulate adenyl cyclase and phopholipase C via 
Gs proteins, which in turn, generates classic second messengers such as the cyclic 
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adenosine monophosphate (cAMP), inositol trisphosphate and Ca+ and induces the release 
of the epidermal growth factor (Filardo et al., 2002). On the other hand, the ER-X is a plasma 
membrane ER enriched in a caveolar-like microdomain that is expressed during 
development and after ischemic brain injury (Toran-Allerand et al., 2005).  ER-X mediates 
17┙-estradiol and 17 ┚-estradiol (E2) activation of MAPK/ERK in development neocortical 
explants, after ischemic injury and in animal models of Alzheimer’s disease and Down’s 
syndrome. These characteristics could explain estrogen’s rapid actions in the central nervous 
system.  
2. Monoamines and depression 
One of the earliest theories in the biology of depression is the monoaminergic hypothesis that 
proposed a dysfunction of the serotonegic/catecholaminergic function that leads to 
depression. The neurotransmitters serotonin (5-HT), dopamine (DA) and noradrenaline (NA) 
(NA) are localized in limbic brain regions involved in the regulation of mood, cognition and 
anxiety, among others. This theory was proposed in the early 50s, with the observation that 
reserpine, a drug with antihypertensive activity and that inhibits catecholamine vesiculation, 
induced signs of depression (Lopez-Muñoz & Alamo, 2009). On the other hand, drugs that 
facilitate monoamine release were found to be antidepressant. At present, serotonin 
transporters, noradrenaline transporters and the monoamine oxidase enzyme (MAO) are 
targets of antidepressant therapy, all of which increase the serotonergic and/or noradrenaline 
tone through an inhibition of monoamine reuptake or inhibition of monoamine catabolism 
(MAO inhibition) (Kalia, 2005; Lopez-Muñoz & Alamo, 2009; Osterlund, 2009).  
Although the pharmacological and biochemical effects of antidepressant drugs occur 
rapidly (within minutes), in clinical practice the antidepressants drugs produce their 
therapeutic actions after at least 10 to 14 days after treatment initiation. This suggests that 
antidepressants act via a delayed postsynaptic receptor-mediated event (Kalia, 2005). It is 
hypothesized that the delayed time of onset for antidepressant drugs is due to the feedback 
mechanism of the somatodendritic 5-HT1A receptor. In this case, increased release of 
serotonin by acute administration of antidepressants such as the selective serotonin 
reuptake inhibitors (SSRIs) leads to a dose-dependent inhibition of 5-HT neuronal firing rate 
(Osterlund, 2009) due to the activation of the presynaptic 5-HT1A receptors, followed by 
inhibition of neuronal firing and terminal serotonin release. Chronic administration of 
reuptake inhibitors leads to desensitization of the presynaptic 5-HT1A autoreceptors and 
thereby restores serotonergic firing and terminal serotonin release (Krishnan & Nestler, 
2008). The observed desensitization of presynaptic 5-HT1A autoreceptors is in line with the 
time course for therapeutic onset of reuptake inhibitors (Maletic et al., 2007; Osterlund, 
2009). 
Similarly to serotonergic receptors, it has been reported that chronic antidepressant 
treatments caused subsensitivity of the noradrenergic receptor–coupled adenylate cyclase 
system in the brain (Vetulani et al., 1976). This work shifted the emphasis from acute 
presynaptic (┙2-adrenergic receptors) to delayed postsynaptic receptor-mediated events in 
the mode of action of antidepressants. The delayed desensitization of the noradrenergic ┚-
adrenoceptor– coupled adenylate-cylase system in the brain is an action that is common to 
almost all antidepressant treatments (Kalia, 2005). 
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3. Depression in women: Role of estrogens 
In women, changes in the incidence of mental illnesses (particularly in major depressive 
disorder) can be found in three important periods of their reproductive life span. These 
periods are characterized by drastic hormonal oscilations (Girdler & Klatzkin, 2007; Payne et 
al., 2007). For example, a correlation was found between the onset of depressive and anxiety 
symptoms and the rapid decrease of progesterone and allopregnanolone levels during the 
late lutheal phase of the menstrual cycle in vulnerable women (Halbreich & Kahn, 2001; 
Backstrom et al., 2003); by contrast, when a gradual reduction in progesterone 
concentrations occurs, a reduction of depression, anxiety, food cravings, mood swings and 
cramps is observed (Contreras et al., 2006). In addition, a positive correlation between the 
abrupt fall of hormones levels and post-partum depression has been established (Jensvold, 
1996). Hence, some reports indicate that hormones such as estradiol are a useful therapy to 
relief the postpartum depression symptoms (Soares et al., 2001).  
The most characterized endocrine period where hormonal fluctuations influence depressive 
states is the perimenopause transition. Several reports indicate that follicular stimulating 
and luteinizing hormones and  estradiol oscillations are correlated with the onset or 
worsening of depression symptoms during early perimenopause (Halbreich & Kahn, 2001; 
Pae et al., 2009), when major depressive disorder incidence is 3-5 times higher than the male 
matched population of the same aged (Riecher-Rossler & Geyter, 2007). Several longitudinal 
studies that followed women across the menopausal transition indicate that the risk for 
significant depressive symptoms increases during the menopausal transition and then 
decreases in the early postmenopause (Soares & Zitek, 2008) and in the last years of 
menopause its incidence is comparable to that shown by men (Payne et al., 2007; Riecher-
Rossler & Geyter, 2007). Also, epidemiological studies showed that women vulnerable to 
hormonal fluctuations, who suffer premenstrual dysphoric disorders, are susceptible to 
develop post-partum- and perimenopausal-depression (Richards et al., 2006; Payne et al., 
2007). The sum of all these depressive episodes results in a long term deficient quality of life 
due to many years of poor mental health. 
Other studies that have shown the participation of estrogens in the etiology of depression 
are the following: a prospective study showed that women with a lifetime history of 
depression had high levels of follicle-stimulating and luteinizing hormones levels, but low 
estradiol concentrations (Harlow et al., 2003). In this case, authors concluded that a lifetime 
history of major depression may be associated with an early decline of ovarian function, a 
situation that characterizes menopause transition (Harlow et al., 2003). On the other hand, in 
a similar study, women with no history of depression, had increased levels of FSH and LH 
and increased variability of estradiol that were significantly associated with depressive 
symptoms (Freeman et al., 2006). In fact, it was proposed that the unstable and irregular 
pattern of hormone production during perimenopausal transition, in susceptible women, 
may increase vulnerability to mood disorders (Sherwin & Henry, 2008; Rocca et al., 2010).   
In addition, it has been reported that in depressive women, high levels of FSH correlate with 
the severity of depression and the intensity of menopausal symptoms (Rajewska & 
Rybakowski, 2003). Interestingly, these women presented a transient decreased response to 
the stimulation of the serotonergic system with D-fenfluramine, suggesting hypoactivity of 
the serotonergic system during depression (Rajewska & Rybakowski, 2003).  Therefore, the 
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impact of hormone oscillations during perimenopause transition may affect the serotonergic 
system function and increase vulnerability to develop depression.   
4. Antidepressant like actions of estrogens in clinical and preclinical studies 
4.1 Effects of estrogens in clinical studies 
The participation of estrogens in the etiology of depression is evident when they are used as 
part of the pharmacotherapy of depression associated to perimenopause. Clinical research has 
found clear antidepressant effects of various estrogens when given alone (Schmidt et al., 2000; 
Soares et al., 2001) or in combination with classic antidepressants (Soares et al., 2001; Morgan et 
al., 2005). However, an equal amount of reports have failed to find antidepressant effects of 
estrogens administered alone (Coope, 1975; Saletu et al., 1995; Morrison et al., 2004) or a lack of 
further benefit from that produced by an antidepressant treatment (Shapira et al., 1985; 
Amsterdam et al., 1999). The nature of such differences is unknown; however, factors, including 
age, type of compounds, depression scales, duration of treatment, type of depression, endocrine 
stage and time after cessation of menses, may be responsible for these differences. 
For example, in a double-blind placebo-controlled study of 34 perimenopausal women with 
major depressive disorder or minor depression, 3 weeks of estradiol monotherapy resulted in 
significant improvement (Schmidt et al., 2000).  Furthermore, in another placebo controlled 
double-blind study of perimenopausal women, 17 -estradiol delivered transdermally was 
also efficacious (Soares et al., 2001). An open study also showed that in women with major 
depressive disorder, estradiol either as monotherapy or added to an SSRI antidepressant was 
effective after 6 weeks of treatment (Rasgon et al., 2002). However, studies in which 
menopausal women with or without depression diagnosis were included, estrogens were 
ineffective to reduce depressive symptoms (Coope, 1975; Strickler et al., 1977). 
On the other hand, two out of four studies of varying designs suggest that estrogen may 
improve responsiveness to antidepressants. A randomized, controlled, multicenter trial of 
fluoxetine in geriatric depression found that women who were incidentally taking estrogen 
improved better on fluoxetine than placebo, whereas those who were not taking estrogen 
showed no difference between fluoxetine and placebo (Schneider et al., 1997). On the 
negative side, a recent retrospective study found no difference in the proportion of 
responders to fluoxetine between women who took estrogen replacement therapy and 
women who did not (Amsterdam et al., 1999). Finally, another study failed to show efficacy 
for estrogen augmentation of imipramine in either pre- or postmenopausal women with 
treatment-resistant depression (Shapira et al., 1985). Some examples of estrogens used as 
therapy for depression alone or in combination with antidepressants or other hormones are 
illustrated in table 1 and table 2. 
4.2 Antidepressant-like effects of estrogens on basic research 
In basic research, animal models of experimental depression have been extensively used in 
the development of novel therapeutic compounds and for the understanding of the neural 
substrates underlying depressive behavior (Holmes, 2003; Cryan et al., 2005; Markou et al., 
2009). Thus, using animal models for the screening of compounds with antidepressant-like 
properties, estrogens have antidepressant-like effects. For example, it was found that 7 days 
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of estradiol treatment reduces the immobility behavior in gonadectomized mice in the tail 
suspension test, suggesting an antidepressant-like action (Bernardi et al., 1989).  
Other studies have been performed in rats and mice using the forced swimming test (FST) 
which has been primarily developed as a test for screening the efficacy of novel 
antidepressants  (López-Rubalcava et al., 2009). It is noticeable that antidepressant-like 
actions of estrogenic compounds have been detected after acute (1 injection) and chronic 
treatments (7-14 days) if they are administered close to the time of ovaries elimination, i. e. 
either immediately or few weeks after estrogens decline. For example, the administration of 
estradiol benzoate for 7 or 14 days, induces antidepressant-like effects in the FST (Okada et 
al., 1997; Rachman et al., 1998). Besides, the antidepressant-like action of estrogenic 
compounds like 17┚-estradiol (E2), 17┙-ethinyl-estradiol (EE2) and diarylpropionitrile 
(DPN, an agonist to estrogen receptors type ┚) was also observed after an acute treatment 
(Estrada-Camarena et al., 2003; Walf et al., 2004). Interestingly, a selective estrogen receptor 
modulator, raloxifene, was only effective after 7 days of treatment; whereas tamoxifen, or 
the ER┙ agonist, 4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) were ineffective 
in the FST after an acute or chronic treatment  (table 3). Hence, the antidepressant-like effect 
of compounds with estrogenic activity depends on the type of compound and on the length 
of the treatment, suggesting that different mechanisms are involved. In addition, the 
antidepressant-like effect of estrogens also seems to depend on the time of estrogen 
restitution after the ovariectomy (OVX) as well as on the age of the animals. In this sense, if 
the restitution with E2 in young animals is initiated after three weeks post-OVX, but not five 
or more weeks, antidepressant-like effects are observed (Estrada-Camarena et al., 2011). In 
contrast, if middle age rats (around 12 months old) are ovariectomized, the antidepressant-
like effect of E2 is restricted to one week post-OVX (unpublished data). 
5. Actions of estrogens on monoaminergic systems 
5.1 Evidence of estrogens interactions with the serotonegic system 
In vitro and in vivo studies, with non-stressed animals, have analyzed estrogens’ effects on 
the serotonergic system. For example, in ovariectomized rats, acute and chronic estradiol 
treatment resulted in increased serotonin levels in specific brain areas such as the dorsal 
raphe nucleus and hippocampus (Lubbers et al., 2010). Similar results were found in the 
hypothalamus of guinea pigs (Lu et al., 1999) and in the dorsal raphe nucleus of nonhuman 
primates (Lu & Bethea, 2002). Furthermore, human studies reported increased serotonin 
levels in postmenopausal women receiving hormone replacement therapy with estrogens 
(Blum et al., 1996) and suggest that estradiol enhances 5-HT synthesis in serotonergic 
neurons (O'Keane et al., 1991).  
Estrogens effects on serotonin levels could be related with an increase on tryptophan 
hydroxylase activity (Donner & Handa, 2009). Thus, in rat´s dorsal raphe nucleus, it has 
been shown that the tryptophan hydroxylase enzyme expression is directly modulated by 
estrogens (McEwen, 1999; Donner & Handa, 2009). Furthermore, inmunohistochemical 
studies revealed the existence of ER- mRNA in neurons of the dorsal raphe nucleus 
(McEwen, 1999). Therefore, it is suggested that estrogens might modulate the enzyme’s 
activity or synthesis through ER-, and consequently have an impact on serotonin levels 
(McEwen, 1999; Donner & Handa, 2009). 
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Another site of action through which estrogens can influence serotonin levels is the serotonin 
transporter (SERT). Studies in monkeys showed that E2 and the selective modulators of 
estrogen receptors, raloxifene and arzoxifene, increased tryptophan hydroxylase mRNA 
expression and decreased SERT’s mRNA expression (Bethea et al., 2002; Smith et al., 2004). 
Interestingly, in the FST, raloxifene induced antidepressant-like effects similar to SSRIs such as 
fluoxetine (Estrada-Camarena et al., 2003; Estrada-Camarena et al., 2010). Studies in rats, 
analyzing different brain areas, indicate that acute or chronic treatment with estradiol 
benzoate decreased the number of 3[H] paroxetine binding sites (Mendelson et al., 1993). These 
results are in agreement with in vitro studies that reported that some estrogenic compounds 
interact with the serotonin transporter in membranes obtained from cerebral cortex, 
hippocampus, hypothalamus and striatum (Chang & Chang, 1999). 
 
Reference Study population 
Estrogenic 
compound 
Findings 
(Lopez-
Jaramillo et 
al., 1996) 
Post-menopausal women
Conjugate equine 
estrogens, oral 
E>placebo 
 Beck scale 
(Soares et al., 
2001) 
Perimenopausal women 
with depression (40-45 
years old) 
17 -estradiol path 
E>placebo 
 MADRS y BKMI 
scales 
(Montgomery 
et al., 1987) 
Peri, postmenopausal 
and hysterectomized  
women without 
depression (44-50 years 
old) 
17 -estradiol with or 
without testosterone 
E o E+T > placebo in 
perimenopausic 
interview and SRD30 
(Strickler et 
al., 1977) 
Perimenopausal and 
hysterectomized women 
with unipolar and bipolar 
depression or healthy (35-
66 years old) 
Conjugate equine 
estrogens, oral 
E=placebo 
MMPI y 16PF scales 
(Coope, 1975) 
Menopausal, 
hysterectomized and 
oophorectomized women 
with depression (40-61 
years old) 
Conjugate equine 
estrogens, oral 
E=placebo 
(Bukulmez et 
al., 2001) 
Postmenopausal women 
without depression 
(45-60 years old) 
Equine estrogens + 
medroxyprogesterone 
or 
Tibolone, oral 
E+MHP o 
E+tibolone>placebo 
 Beck scale 
(Schmidt et 
al., 2000) 
Perimenopausal women 
with depression 
17 -estradiol patch E>placebo 
Table 1. Effect of estrogens as antidepressants in clinical practice 
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Reference Study population Antidepressant Type of estrogen Results 
(Shapira et 
al., 1985) 
Pre and 
postmenopausal  
women with 
depression 
treatment 
resistant  (26-74 
years old) 
Imipramine 
200 mg/day/3 
months 
Conjugate equine 
estrogens, oral 
1.25-3.75 
mg/day/month 
E+imipramine = 
placebo+imipramine 
Hamilton and 
Becker scales 
(Amsterdam 
et al., 1999) 
Pre and 
postmenopausal  
women with 
depression with 
or without 
treatment with 
estrogens alone or 
in combination 
with progesterone 
(<45 a > 45) 
Fluoxetine 
20 mg/day/3 
months 
Conjugate equine 
estrogens, oral 
0.625 mg/day/3 
months with or 
without 
progesterone 
E+fluoxetine= 
placebo+fluoxetine 
Hamilton scale 
(Schneider 
et al., 1997) 
postmenopausal  
women with 
depression 
Fluoxetine 
ERT Estrogens 
1.5 month 
E+FLX >E+placebo, 
placebo+FLX y 
placebo+placebo 
(Schneider 
et al., 2001) 
postmenopausal  
women with 
depression > 60 
years old 
Sertraline 
Conjugate equine 
estrogones oral 
(0.625 mg/day) 
/3 months 
E+SERT improves of 
quality of life 
(Soares et al., 
2001) 
Peri and post-
menopausal 
women with 
depression 
Citalopram 
20-40 
mg/day/2 
months 
17 -estradiol 
(100 µg/day/1 
month + CIT/2 
months 
E+CIT> E+placebo 
 MADRS scale 
(Joffe et al., 
2001) 
Peri and post-
menopausal 
women with 
depression 
Mirtazepine 
30-45 mg/day
2 months 
estrogens+MIRT
E+MIRT 
 Hamilton scale 
 
 
Table 2. Effect of estrogens combination with antidepressant drugs in the treatment of 
depression  
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Estrogenic compound 
Behavioral 
effect 
Test References 
Agonist with more activity 
on ER┙    
Propyl-pyrazol-triol (PPT) 
17┙-estradiol 
17┙-Ethynyl-estradiol 
- 
- 
+   Low doses 
-  High doses 
FST 
FST 
FST 
FST 
(Estrada-Camarena et al., 
2003; Walf et al., 2004; Walf 
& Frye, 2007) 
Agonist  with more activity 
on ER┚    
Diaryl-propionitrile (DPN) 
Cumestrol 
 
+ 
+ 
FST 
FST 
(Walf et al., 2004; Walf & 
Frye, 2007) 
    
Agonist of GPR30    
G1 + TST (Dennis et al., 2009) 
    
Agonist of ER┙ and ER┚    
17 ┚-Estradiol* 
Estradiol benzoate * 
Diethyl-stilbestrol 
Estradiol valerate 
 
+ 
+/- 
- 
+ 
FST 
FST, TST 
FST 
CMS 
(Bernardi et al., 1989; Okada 
et al., 1997; Rachman et al., 
1998; Galea et al., 2002; 
Estrada-Camarena et al., 
2003; Dalla et al., 2005; 
Romano-Torres & 
Fernandez-Guasti, 2010) 
Selective estrogen receptor 
modulators of ER┙ and 
ER┚ 
   
Raloxifene 
Tamoxifen 
 
+ 
- 
FST 
FST 
(Estrada-Camarena et al., 
2010; Walf & Frye, 2010) 
Antagonist of ER┙ and ER┚    
RU 58668 
ICI 182780 
- 
- 
FST 
FST 
(Estrada-Camarena et al., 
2006b; López-Rubalcava et 
al., 2007) 
    
Phytoestrogens    
Pomegranate (Estradiol, 
estrone, estriol, cumestrol, 
genistien) 
+ FST (Mori-Okamoto et al., 2004) 
FST=Forced swimming test; TST= tail suspension test; CMS = chronic mild stress. +: decrease of 
anhedonia or immobility behavior; - : no change of anhedonia or immobility behavior 
Table 3. Effect of different types of estrogenic compounds in ovariectomized female rodents 
tested in different animal models for the screening of antidepressant-drugs. 
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As for the action of estrogens on serotonergic receptors, an interaction with 5-HT1A, 5-HT1B 
5-HT2A/2C and 5-HT3 receptors has been demonstrated (Osterlund & Hurd, 1998; Raap et 
al., 2000; Hiroi & Neumaier, 2009). In general, it is proposed that estrogens produce a 
desensitization of 5-HT1A receptors (Lu & Bethea, 2002) which is associated with decreased 
Gi protein coupled receptors (Mize & Alper, 2000; Raap et al., 2000; Lu & Bethea, 2002). 
Moreover, another mechanism of action involves the phosphorylation of 5-HT1A receptor 
via activation of protein kinase-A; this effect is proposed to be mediated through the 
activation of an estrogen membrane receptor (Mize & Alper, 2002). 
Recently, our laboratory found that E2 requires the presence of 5-HT since its depletion or 
the selective destruction of the presynaptic terminal, partially blocked E2’s antidepressant-
like effects (López-Rubalcava et al., 2005). Furtheremore, the antidepressant-like actions of 
E2 and EE2, alone or in combination with fluoxetine require the activation of 5-HT1A 
receptors, since the selective 5-HT1A antagonist, WAY100635 blocked the antidepressant-
like effect induced by these estrogens (Estrada-Camarena et al., 2006a; Estrada-Camarena et 
al., 2006b). In support of this proposal, the administration of the specific 5-HT1A post-
synaptic receptor antagonist MM-77, canceled E2 antidepressant-like effects in the FST 
(López-Rubalcava et al., 2005). 
Results suggest that estrogenic actions on the serotonergic system require estrogen receptor 
activation. For example, our research group found that RU58688, an estrogen receptor 
antagonist, blocks E2 antidepressant-like effects in the FST (Estrada-Camarena et al., 2006b); 
while the desensitization of postsynaptic 5-HT1A receptors located in the hippocampus of 
the rat requires the participation of a membrane estrogen receptor (Mize et al., 2001). 
Recently, it was demonstrated that the membrane estrogen receptor GPR30, is involved in 5-
HT1A receptor desensitization in the hypothalamus of the rat (Rossi et al., 2010). Taken 
together, these data may explain why the blockade of ER and 5-HT1A receptor cancels E2 
antidepressant-like effects. 
In conclusion, it can be proposed that the antidepressant-like effects of E2 are due to its effects 
on the serotonergic system at both, a pre-and post-synaptic terminals. Thus, in the presynaptic 
neuron, estrogens are likely to stimulate the activity of the enzyme tryptophan hydroxylase and 
at the same time inhibit the SERT, this would lead to an increased in the availability of 5-HT in 
the synaptic cleft. On the postsynaptic site, 5-HT1A and possibly 5-HT2A receptors contribute 
to trigger signaling cascades that would allowed the modulation of other neurotransmitter 
systems and processes as complex as the modulation of neuronal plasticity (Fig. 1). 
5.2 Evidence of the interaction of estrogens with the noradrenergic system 
Several reports, including electrophysiological records (Wagner et al., 2001) and ligand 
binding studies (Wilkinson & Herdon, 1982) have shown that estrogens can also modulate 
noradrenergic neurotransmission in the central nervous system (CNS). Several studies 
reported that estrogenic compounds can influence noradrenergic neurotransmission 
through an interaction with the noradrenergic transporter and the MAO or tyrosine 
hydroxylase enzymes. For example, in vitro studies have shown that E2, EE2, DES and some 
catechol-estrogens such as 2-hydroxy-EE2 (2-OH-EE2) and 2-hydroxy-E1 (2-OHE) inhibit 
NA reuptake sites in synaptosomes from the cerebral cortex and hypothalamus of rats that 
resulted in increased levels of NA in the synaptic cleft (Ghraf et al., 1983). In line with these 
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findings, acute E2 administration to ovariectomized rats decreased NA reuptake rate in the 
hypothalamus (Hiemke et al., 1985) and increases mRNA levels of tyrosine hydroxylase in 
the locus coeruleus (Serova et al., 2002).  Finally, it has been reported that estrogens 
increased NA concentration by inhibiting MAO-A activity (Holschneider et al., 1998). These 
data collectively suggest that estrogens interact with the noradrenergic system through the 
modulation of NA release, as well as in processes of synthesis and elimination of the 
neurotransmitter. Thus, E2 given to ovariectomized female rats increased the firing rate of 
noradrenergic neurons that project to the preoptic area and to the anterior hypothalamus 
(Kaba et al., 1983). Similarly to some antidepressant drugs, such as desipramine 
(noradrenergic reuptake inhibitor), E2 decreased mRNA expression and density of ┙2 
receptors (Karkanias et al., 1997); it has been reported that chronic treatment with E2 reduces 
┚ adrenergic receptors response (Carlberg & Fregly, 1986). 
 
Fig. 1. Esquematic representation of proposed mechanism of action of estradiol’s 
antidepressant-like actions on the serotonergic system in the forced swimming test (an 
animal model of depression). First, estradiol increases the activity of tryptophan 
hydroxylase and inhibits the serotonin transporter to induce an increase in serotonin levels 
in the synaptic clef. Second, estradiol could also induce a desensitization of 5-HT1A and 5-
HT1B presynaptic receptors and modulate serotonin release and firing of serotonergic 
neurons; as a consequence, the increase of serotonin in the synaptic clef may activate 5-
HT1A and 5-HT2A postsynaptic receptors and promote the activation of signal transduction 
pathways. SERT= serotonin transporter. 
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On the same research line, it has been suggested that EE2 interaction with the noradrenergic 
system may be mediated through ┙2 adrenergic receptors, since idazoxan, a selective 
antagonist of these receptors, is able to block the antidepressant-like effect of EE2 (López-
Rubalcava et al., 2007). In addition to these studies, recently we have found that the DSP4, a 
neurotoxin that selectively destroys noradrenergic nerve terminals in the locus coeruleus 
was able to blocked the antidepressant-like effects  induced by EE2 in the FST (López-
Rubalcava et al., 2007). Together, these findings suggest that estrogen may facilitate the 
noradrenergic transmission by: 1) increasing NA synthesis, 2) by reducing NA reuptake, 
and by improving NA availability, or 3) through a mechanism involving both proposals.  
5.3 Evidence of estrogens interactions with the dopaminergic system 
The finding that some estrogens increase the activity of tyrosine-hydroxylase enzymes and 
inhibit the MAO-A activity may lead to the speculation that an increase in dopaminergic 
activity could mediate the antidepressant-like effect of estrogens.  To our knowledge, there is no 
direct correlation between brain levels of dopamine or its metabolites and the antidepressant-
like effect of these steroids. However, some preclinical reports indicates that agonist to ER┙ 
increase dopamine and DOPAC (dopamine metabolite) levels in the hippocampus and the 
frontal cortex (Lubbers et al., 2010), areas involved in the effect of several antidepressant drugs. 
In fact, bupropion, a catecholamine enhancer, produces antidepressant-like actions in preclinical 
models (Reneric & Lucki, 1998; Dhir & Kulkarni, 2008; Bourin et al., 2009).    
Evidences in non-stressed animals also support the effect of estrogens on the dopaminergic 
system. For example, ovariectomy induces a decrease in D1 and D2 receptors density (Bosse 
& DiPaolo, 1996) which is reverse by 17┚-estradiol chronic treatment (Bosse & DiPaolo, 1996; 
Landry et al., 2002). In acute treatment, estradiol does not alter D2 receptors density but 
induces changes in the proportion of high to low affinity sites (Levesque & Di Paolo, 1993). 
In relation to the dopamine transporter (DAT), it has been shown that ovariectomy increases 
the DAT in the striatum, and this increase was reverted by estradiol chronic treatment 
(Attali et al., 1997).  
It has been reported that D1 and D2 receptor blockade may contribute to reduce negative 
effects derived from the Hypothalamus-Pituitary-adrenal axis (HPA) activation during stress 
response (Sullivan & Dufresne, 2006; Belda & Armario, 2009).  For example, the administration 
of dopamine agonists in different brain areas resulted in the increase of plasma corticosterone 
levels (Ikemoto & Goeders, 1998), whereas the administration of antagonists to D1 and D2 
receptors reduces the increase in plasma ACTH and corticosterone concentrations induced by 
stress (Belda & Armario, 2009). Thus, it is suggested that dopamine receptors are involved in 
the regulation of the stress response (Belda & Armario, 2009).   
In addition, in transgenic mice with functional alterations of the HPA axis, the antidepressant 
treatment with FLX or amitryptiline corrected the increased binding on D1 and D2 receptors in 
the striatum and decreased dopamine transporter levels (Cyr et al., 2001). Therefore, if 
estrogens are able to modulate dopamine receptors and DAT, it is possible that these effects 
contribute to explain their antidepressant-like effect. Supporting this assumption, a recent 
report in ovariectomized rats shows that chronic administration of SCH 23390 (D1 antagonist) 
plus E2 induces robust antidepressant-like actions in the FST (Fedotova & Ordyan, 2011).   
Additionally, in an experiment performed in male mice it was found that the blockage of D1 or 
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D2 receptors cancelled the antidepressant-like action of the acute administration of E2 (Dhir & 
Kulkarni, 2008). Consequently, the information about the specific participation of 
dopaminergic receptors in the antidepressant-like action of estrogens is yet controversial and 
need further exploration in order to establish any conclusion. 
6. Proposed mechanism of action in the antidepressant-like effects of 
estrogens 
As mentioned earlier, estrogens increases the activity of enzymes involved in the synthesis 
of 5-HT (tryptophan hydroxylase) and catecholamines (tyrosine hydroxylase and dopamine 
┚-hydroxylase) at the same time that posses the ability to inhibit or decrease the activity of 
the serotonin and noradrenaline transporters in several brain areas. Interestingly, at the 
presynaptic terminal, estrogens can also activate the 5-HT1A/5-HT1B and ┙2-adrenoceptor 
that regulates the discharge and release of both NA and 5-HT.  Together, these effects may 
contribute to increase the levels of monoamines in the synaptic clef and promote the 
activation of post-synaptic receptors such as 5-HT2A and ┚-adrenergic receptors as well as 
the activation or deactivation of several signal transduction pathways such as cAMP-PKA 
and IP3-PKC, among others. These signal transduction pathways may contribute to the 
activation of transcription factors like CREB and promote neuroplastic remodeling and/or 
neuroprotection processes (Bethea et al., 2009)  that could be effective in the development of 
strategies to cope with stress. Additionally, it has been reported that E2 administration 
decreases the activity of monoamine oxidase enzymes activity (type A and B) (involved in 
the degradation monoamines) in several areas of brain (Gundlah et al., 2002).  
Recently, it was shown that the monoaminergic neurotransmission is sensitive to 
modulation of estrogenic compounds, in this sense, the effects of estrogens on monoamine 
levels may be dependent of the type of estrogen receptor used; thus, ER┙ or ER┚ agonists 
increases the levels of NA in the frontal cortex and hippocampus; similarly, ER┙ agonist 
increase the levels of the metabolites of NA and dopamine, 3-methoxy-4-
hydroxyphenylglycol (MHPG) and DOPAC in hippocampus or frontal cortex; and ER┚ 
agonist increase the levels of 5-HIIA in amygdala, hippocampus and ventral tegmental area 
(Lubbers et al., 2010). It was shown that that the effects of estrogens on cathecolaminergic 
biosynthetic enzymes are due to the activation of estrogens receptors ┙ and the serotonergic 
enzyme stimulation has been related with the activation of ER  (Donner & Handa, 2009; 
Serova et al., 2010). Therefore, it is possible to considerer that the modulation of serotonergic 
and noradrenergic activity depends in part of the activation of ER. Based on this evidence, it 
seems possible that ER┙ are more related with the modulation of the catecholaminergic 
system, while ER with the serotonergic one; notwithstanding future studies are needed to 
confirm this hypothesis. 
It is important to mention that participation of estrogens’ membrane receptors in  the 
modulation of monoamines activity needs to be further investigated. For example, it has 
been shown that the desensitization of 5-HT1A receptor induced by 17 -estradiol in 
oxytocin cells of hypothalamus is independent of the activation of ER and may involve 
only the membrane estrogen receptor GPR30 (Rossi et al., 2010); while the desensitization of 
the same receptors in the ACTH cells are depend of both GPR30  and ER (Rossi et al., 2010). 
This evidence shows the complexity in the relationship between estrogens and monoamines. 
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Fig. 2. Esquematic representation proposed for the mechanism of action of ethynyl 
estradiol’s antidepressant-like actions on the noradrenergic and serotonergic systems in the 
forced swimming test (an animal model of depression). Ethynyl-estradiol increases tyrosine 
hydroxylase activity and simultaneously inhibits the noradrenergic transporter, facilitating 
the release of noradrenaline. Increases in NA concentration promote ┙2-autoadrenoceptors 
desensitization. In addition, estrogens activate ┙2-adrenoceptors located on the serotonergic 
terminals and, therefore, contribute to regulate serotonin release. NAT= Noradrenergic 
Transporter 
7. Possible implications of estrogens actions on the modulation of 
monoamines activity 
The modulation of noradrenergic and serotonergic systems by estrogens could have 
important physiological implications in the regulation of stress response. It has been 
reported that corticotrophin releasing factor (CRF) stimulates locus coeruleus activity under 
stressful situations and this is associated with a heightened arousal (Valentino & Van 
Bockstaele, 2008; Bangasser et al., 2010). In this case, there is direct evidence that CRF genes 
expression is regulated by estrogens and that estradiol reduces plasma ACTH and blood 
pressure increases induced by restrain stress (Bangasser et al., 2010). These responses 
occurred simultaneously to a differential modulation of cathecolamine biosynthetic 
enzymes gene expression in the nucleus of the solitary tract and the locus coeruleus (Serova 
et al., 2005).  
Recently, it was reported that an animal model of depression, the FST, increased 
corticosterone and estrogen plasma concentrations in adult females rats (Martinez-Mota et 
al., 2011), suggesting that estrogens function as a compensatory mechanism against stress-
response. Furthermore, estradiol administration prevented the increase in the percentage of 
discharge of the locus coeruleus induced by the FST in ovariectomized rats. As a result, it is 
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possible to considerer that estrogens modulation of the noradrenergic system results in an 
increase expression of coping behaviors in the FST and in the regulation of HPA function.  
In addition, it has been reported that stress induced by the FST reduces 5-HT levels in the 
amygdala and lateral septum in male rats (Kirby et al., 1995), while in females, 5-HT is 
reduced in the prefrontal cortex and in the  hypothalamus, but not in the amygdala (Dalla et 
al., 2005).  Interestingly, unpublished results from our laboratory showed that E2 
administration, previous to the FST, prevented the decline of 5-HT concentration in some 
brain areas during the FST and at the same time E2 induces an antidepressant-like effect.   
Therefore it could be suggested that estrogenic compounds contribute to increase the 
serotonergic activity and simultaneously decrease noradrenergic activity, improving the 
behavioral strategies to cope with acute stressful situations. Also these protective actions of 
estrogens have been shown using animal models of chronic stress; in this case, estradiol 
administration reversed chronic stress-induced sensitization in the paraventricular nucleus 
and central amygdala of female rats (Gerrits et al., 2006). 
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